Octreotide Acetate

5 trials 3 recruiting HEndocrinology

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

3 Recruiting

1 Completed trials

5 Sponsors

15 Countries

Phase III

Phase II

Phase IV

Phase III: 1 Phase II: 3 Phase IV: 1

Oversight events:

7 temporary halts across 1 trial

View oversight register →

Indications tested

Acromegaly 1 Meningioma 1 Gastroenteropancreatic neuroendocrine tumour disease 1 Carcinoid syndrome 1

Sponsors using this IMP

Alexion Pharmaceuticals Inc. 1 Amsterdam UMC Stichting 1 Crinetics Pharmaceuticals Inc. 1 Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi 1 Novartis Pharma AG 1

All trials

5 total

Study to evaluate the efficacy and safety of [177Lu]Lu-DOTA-TATE in patients with Grade 1 and Grade 2 advanced GEP-NET (NETTER-3) Recruiting

2024-518325-15-00 Phase III 7 countries Novartis Pharma AG
Preventing postoperative complications in patients undergoing high-risk pancreatoduodenectomy with a bundle approach including hydrocortison… Recruiting

2024-519667-18-00 Phase IV 7 countries Amsterdam UMC Stichting
Lutathera for the treatment of recurrent Meningioma (LUMEN-1) Recruiting

2024-513443-93-00 Phase II 8 countries Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europ…
Phase 2 Study of ALXN2420 versus Placebo in Combination with Somatostatin Analogs in Participants with Acromegaly Halted

2025-521243-20-00 Phase II 7 countries Alexion Pharmaceuticals Inc.
Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Treatment in Subjects with Carcinoid Syndrome Ended

2024-511922-30-00 Phase II 1 country Crinetics Pharmaceuticals Inc.

Showing 1–5 of 5 trials

← All drugs A–Z